JP2010524432A - サーチュイン活性のバイオマーカーおよびその使用方法 - Google Patents

サーチュイン活性のバイオマーカーおよびその使用方法 Download PDF

Info

Publication number
JP2010524432A
JP2010524432A JP2009554564A JP2009554564A JP2010524432A JP 2010524432 A JP2010524432 A JP 2010524432A JP 2009554564 A JP2009554564 A JP 2009554564A JP 2009554564 A JP2009554564 A JP 2009554564A JP 2010524432 A JP2010524432 A JP 2010524432A
Authority
JP
Japan
Prior art keywords
sirtuin
biomarker
subject
expression level
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009554564A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010524432A5 (https=
Inventor
オリビエ ボス，
シバ ラブ，
アンドレ イフラント，
ジェシー ジェイ． スミス，
ジル ミルン，
マイケル ジローセク，
Original Assignee
サートリス ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サートリス ファーマシューティカルズ， インコーポレイテッド filed Critical サートリス ファーマシューティカルズ， インコーポレイテッド
Publication of JP2010524432A publication Critical patent/JP2010524432A/ja
Publication of JP2010524432A5 publication Critical patent/JP2010524432A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Child & Adolescent Psychology (AREA)
JP2009554564A 2007-03-19 2008-03-19 サーチュイン活性のバイオマーカーおよびその使用方法 Pending JP2010524432A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91873507P 2007-03-19 2007-03-19
PCT/US2008/003605 WO2008115518A2 (en) 2007-03-19 2008-03-19 Biomarkers of sirtuin activity and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2010524432A true JP2010524432A (ja) 2010-07-22
JP2010524432A5 JP2010524432A5 (https=) 2011-05-06

Family

ID=39708658

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009554564A Pending JP2010524432A (ja) 2007-03-19 2008-03-19 サーチュイン活性のバイオマーカーおよびその使用方法

Country Status (6)

Country Link
US (1) US20100215632A1 (https=)
EP (1) EP2126109A2 (https=)
JP (1) JP2010524432A (https=)
AU (1) AU2008229385A1 (https=)
CA (1) CA2680823A1 (https=)
WO (1) WO2008115518A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102559850A (zh) * 2010-12-16 2012-07-11 广州益善生物技术有限公司 一种apoA5基因突变检测特异性引物和液相芯片
JPWO2013024821A1 (ja) * 2011-08-12 2015-03-05 国立大学法人 筑波大学 並列反応用懸濁液、並列反応方法およびスクリーニング方法
KR102127903B1 (ko) * 2019-01-29 2020-06-29 연세대학교 산학협력단 염증성 호흡기 질환의 진단용 바이오마커

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
US11207518B2 (en) * 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
EP1955077B1 (en) * 2005-12-02 2012-06-13 Sirtris Pharmaceuticals, Inc. Mass spectrometry assays for acetyltransferase/deacetylase activity
US8391970B2 (en) * 2007-08-27 2013-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
US9211409B2 (en) 2008-03-31 2015-12-15 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of T-cell activity
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
EA021938B1 (ru) 2008-05-01 2015-10-30 Сертрис Фармасьютикалз, Инк. Хинолины и их аналоги в качестве модуляторов сиртуина
AU2009266889B2 (en) 2008-07-03 2013-05-02 Glaxosmithkline Llc Benzimidazoles and related analogs as sirtuin modulators
MX349176B (es) * 2008-09-22 2017-07-14 Biochemics Inc Suministro transdermico de farmaco empleando un osmolito y un agente vasoactivo.
US9326986B2 (en) 2008-09-29 2016-05-03 Glaxosmithkline Llc Quinazolinone, quinolone and related analogs as sirtuin modulators
BRPI0806044A2 (pt) * 2008-10-17 2010-09-14 União Brasileira De Educação E Assistência - Mantenedora Da Pucrs método e kit para determinação de agentes moduladores de sirtuìnas, processo para modulação de sirtuìnas, compostos moduladores de sirtuìnas e composições compreendendo os mesmos
ES2452484T3 (es) 2008-11-18 2014-04-01 Setpoint Medical Corporation Dispositivos para optimizar la colocación de electrodos para la estimulación antiinflamatoria
US20110054569A1 (en) * 2009-09-01 2011-03-03 Zitnik Ralph J Prescription pad for treatment of inflammatory disorders
US8996116B2 (en) * 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
WO2010144578A2 (en) 2009-06-09 2010-12-16 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US9556201B2 (en) 2009-10-29 2017-01-31 Glaxosmithkline Llc Bicyclic pyridines and analogs as sirtuin modulators
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
WO2014169145A1 (en) 2013-04-10 2014-10-16 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
CN105126248B (zh) 2009-12-23 2018-06-12 赛博恩特医疗器械公司 用于治疗慢性炎症的神经刺激设备和系统
CN102985553B (zh) * 2010-04-15 2015-11-25 西特里斯药业公司 沉默调节蛋白活化剂和活化测定
RU2018110642A (ru) 2010-05-03 2019-02-27 Курна, Инк. Лечение заболеваний, связанных с сиртуином (sirt), путем ингибирования природного антисмыслового транскрипта к сиртуину (sirt)
EP2707094B1 (en) 2011-05-09 2016-02-03 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US12172017B2 (en) 2011-05-09 2024-12-24 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
RU2612630C2 (ru) * 2014-09-17 2017-03-09 Федеральное бюджетное учреждение науки "Центральный научно-исследовательский институт эпидемиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ЦНИИ Эпидемиологии Роспотребнадзора) Способ определения индивидуального генетического риска развития ишемического инсульта
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
US11406833B2 (en) 2015-02-03 2022-08-09 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
CN108882885A (zh) 2016-01-20 2018-11-23 赛博恩特医疗器械公司 迷走神经刺激的控制
US10314501B2 (en) 2016-01-20 2019-06-11 Setpoint Medical Corporation Implantable microstimulators and inductive charging systems
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
CA3051826A1 (en) * 2017-01-27 2018-08-02 A-Clip Institute, Co., Ltd. Prophylactic and/or therapeutic agent for infectious disease or inflammatory disease
US11173307B2 (en) 2017-08-14 2021-11-16 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
EP3717912A4 (en) * 2017-12-01 2021-10-27 The Scripps Research Institute METHODS AND MATERIALS FOR EVALUATING BIOLOGICAL AGE AND SLOWING THE PROGRESS OF EXCESSIVE BIOLOGICAL AGING
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
US12343535B2 (en) 2019-04-12 2025-07-01 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
AU2021207815B2 (en) 2020-01-13 2026-03-26 The Feinstein Institutes For Medical Research Treating bleeding and bleeding disorders via high intensity focused ultrasound stimulation of the spleen
US11938324B2 (en) 2020-05-21 2024-03-26 The Feinstein Institutes For Medical Research Systems and methods for vagus nerve stimulation
WO2022245878A1 (en) 2021-05-17 2022-11-24 Setpoint Medical Corporation Neurostimulation parameter authentication and expiration system for neurostimulation
US20250229086A1 (en) 2022-01-20 2025-07-17 Setpoint Medical Corporation Treatment of inflammatory disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716626B1 (en) * 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
US20080249103A1 (en) * 2006-11-15 2008-10-09 Sirtris Pharmaceuticals, Inc. Sirtuin polymorphisms and methods of use thereof
US20100168084A1 (en) * 2008-05-08 2010-07-01 Huber L Julie Therapeutic compounds and related methods of use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6013014222; ＭＯＬＥＣＵＬＡＲ　ＡＮＤ　ＣＥＬＬＵＬＡＲ　ＢＩＯＬＯＧＹ Ｖｏｌ．２８，　Ｎｏ．１, 200801, ｐ．１８８-２００ *
JPN6013014223; ＴＲＥＮＤＳ　ｉｎ　Ｐｈａｒｍａｃｏｌｏｇｉｃａｌ　Ｓｃｉｅｎｃｅｓ Ｖｏｌ．２６，　Ｎｏ．２, 2005, ｐ．９４-１０３ *
JPN6013014224; Ｉｎｔｅｒｎａｔｉｏｎａｌ　Ｉｍｍｕｎｏｐｈａｒｍａｃｏｌｏｇｙ Ｖｏｌ．５, 2005, ｐ．３９３-４０６ *
JPN7013001122; Ｊｏｕｒｎａｌ　ｏｆ　Ｖａｓｃｕｌａｒ　Ｒｅｓｅａｒｃｈ Ｖｏｌ．４４, 2007, ｐ．７５-８４ *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102559850A (zh) * 2010-12-16 2012-07-11 广州益善生物技术有限公司 一种apoA5基因突变检测特异性引物和液相芯片
JPWO2013024821A1 (ja) * 2011-08-12 2015-03-05 国立大学法人 筑波大学 並列反応用懸濁液、並列反応方法およびスクリーニング方法
KR102127903B1 (ko) * 2019-01-29 2020-06-29 연세대학교 산학협력단 염증성 호흡기 질환의 진단용 바이오마커

Also Published As

Publication number Publication date
EP2126109A2 (en) 2009-12-02
WO2008115518A2 (en) 2008-09-25
US20100215632A1 (en) 2010-08-26
CA2680823A1 (en) 2008-09-25
AU2008229385A1 (en) 2008-09-25
WO2008115518A3 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
JP2010524432A (ja) サーチュイン活性のバイオマーカーおよびその使用方法
US12012634B2 (en) Methods for diagnosing, prognosing, and treating parkinson's disease or parkinsonism
US20230220468A1 (en) Methods for detecting a genetic variation in attractin-like 1 (atrnl1) gene in subject with parkinson's disease
Taymans et al. Distribution of PINK1 and LRRK2 in rat and mouse brain
US20040115671A1 (en) Gene expression profiling of endothelium in alzheimer's disease
US20050136429A1 (en) SIRT1 modulation of adipogenesis and adipose function
JP2004121218A (ja) 気管支喘息または慢性閉塞性肺疾患の検査方法
CA3121167A1 (en) Methods of stratifying and treating a sub-population of inflammatory bowel disease patients
US20110113498A1 (en) Sirt1 polymorphic variants and methods of use thereof
US10286042B2 (en) Methods for the treatment of neurological disorders and diseases using FNDC5
CN102112879B (zh) Stat3和tyk2作为神经退行性疾病的药物靶点
US20080249103A1 (en) Sirtuin polymorphisms and methods of use thereof
JP2003504007A (ja) 神経変性性疾患における脳の特異的な領域での異なる遺伝子発現
JP7120663B2 (ja) 糖尿病性腎臓病の診断することを補助する方法、糖尿病性腎臓病の検査用キット、動物治療方法、及び糖尿病性腎臓病用医薬
CN120129834A (zh) 用于评估和治疗神经退行性疾病的蛋白质标志物
US20100298438A1 (en) Gene expression profiling of parkinson's disease
Morris et al. NPY mRNA expression in the prefrontal cortex: Selective reduction in the superficial white matter of subjects with schizoaffective disorder
Chen et al. PPP2R2B CAG repeat length in the Han Chinese in Taiwan: Association analyses in neurological and psychiatric disorders and potential functional implications
CN107922485A (zh) 诊断和治疗情绪障碍的方法
Wang et al. S100B gene polymorphisms are associated with the S100B level and Alzheimer’s disease risk by altering the miRNA binding capacity
TW200940990A (en) A diagnostic blood test for psychosis
AU2008318311A1 (en) FGF9-related methods for treating anxiety
KR102916085B1 (ko) 뇌전증 관련 불안 장애에 대한 치료 표적 및 치료용 바이오 마커로서 il-17a의 용도
US20190195859A1 (en) Determining the risk of scoliosis comprising determining cellular response to mechanostimulation
WO2009001095A2 (en) Novel schizophrenia associated genes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110318

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120228

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20121023

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20121031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130326

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130830